biohellenika news 3
DESCRIPTION
Biohellenika's newspaper about stem cells and their medical applicationsTRANSCRIPT
NEWS 03www.biohellenika.gr
To date, 25,000 haematopoietic and free of disease. 30% of stem cell transplantations derived transplantations were allogeneic from the placenta, bone marrow with stem cells sourced from a and peripheral blood have been compatible donor, who was a carried out across Europe. 70% of relative in 70% of the cases, those were autologous; using the whereas in 30% of the cases the patients’ own stem cells. In each donor was unrelated.case the stem cells were healthy n page 2 n page 9
March 2008
Mesenchymal stem cells: The future of modern medicine
Umbilical cord contains both mature and immature progenitor cells, heamatopoietic and mesenchymal stem cells respectively. Haematopoietic stem cells can provide effective treatment for haematopoietic malignancies and diseases of the immune system.
Human Dental Pulp
Stem Cells in the
treatment of Acute
Myocardial InfarctionHuman dental pulp contains
precursor cells termed
Mesenchymal Dental Pulp Stem
Cells (DPSCs) that show high self-
renewal ability and plasticity, like
mesenchymal stem cells, as they
can be differentiated into
multiple cell types.
08
11
Patient from finland gets new
Jaw made of his own cells
n page 5
Present and future applications of umbilical cord blood stem cells
03
Biohellenika SA is the only
Accredited by ÅÓÕÄ Stem Cell
Cryopreservation Company
04
Clinical applications of umbilical
cord blood stem cells for
nonmalignant diseases
06
New applications of umbilical cord
blood mesenchymal stem cells.
Stem cells against diabetes type I
immediate availability when needed, provided that they
have been previously collected and cryopreserved when
the donor was healthy, with the prospect of future use.
Umbilical cord blood stem cells have increasingly been
used for autologous and allogeneic transplantations
and are the treatment of choice in cases of patients with
rare histocompatibility types, ethnic minorities, and
where the patient urgently requires a transplant and
cannot wait for the weeks or months required to search
for a compatible donor.
Tse WW et al. Bone Marrow Transplant. 41(5): 465-472,
2008
Due to the easy attainment and the possibility of To d a t e , 2 5 , 0 0 0 h a e m a t o p o i e t i c s t e m c e l l
umbilical cord blood stem cell cryopreservation it is transplantations derived from the placenta, bone
anticipated that in the near future every child will marrow and peripheral blood have been carried out
across Europe. 70% of those were autologous; using the preserve its own stem cells for immediate use, if needed.
patients’ own stem cells. In each case the stem cells were It is anticipated that the use of umbilical cord blood stem
healthy and free of disease. 30% of transplantations were cells will increase dramatically over the next 4 years for allogeneic with stem cells sourced from a compatible the treatment of Acute Myeloblastic Leukemia, Acute donor, who was a relative in 70% of the cases, whereas in Lymphoblastic Leukemia, lymphomas in children and 30% of the cases the donor was unrelated. In a large adults, and autoimmune and cardiovascular diseases.number of cases cryopreserved stem cells were used.
Stem cell cryopreservation has the advantage of Watt SM et al. Methods Mol Biol, 368:237-259, 2007
03NEWSNEWS02
NEWS
Nr 03
nWhen Ltd companies were claiming to be “the only
ones operating under the guidelines of ISO 15189”,
Biohellenika’s scientific team was striving to improve
the quality of their services provided. On 21/02/2008
Biohellenika attained the 410 08/02/2008 accreditation
by the National Accreditation System S.Á (ÅÓÕÄ) granted
for procedures followed and quality testing of umbilical
cord blood during the collection of stem cells. With this
certification, Biohellenika is accredited according to ISO
15189:2007, special for medical laboratories, for
nucleated cell measurement, haematopoietic stem cell
viability and microbial testing, including aerobic,
anaerobic bacteria and fungi. This certificate is valid until
2012 as long as the facility’s operations comply with the
above guidelines during regular ÅÓÕÄ inspections.
The National Accreditation System (ÅÓÕÄ ) is a full
member of the International Laboratory Accreditation
Cooperation (ILAC) since 2004, of the European
Cooperation for Accreditation – EA since 2005, and of the
International Accreditation Forum (IAF-MRA) since 2006.
The international identity of ÅÓÕÄ gives the
perspective of the parity and mutual recognition of
accreditation between countries. Biohellenika today is
the first company in Greece whose laboratories are
accredited by a national independent organization for
measurements and quality control procedures followed
during stem cell collection from umbilical cord blood.
Áñ. 410
Ôo Åèíéêü Óýóôçìá Äéáðßóôåõóçò Á.Å. (Å.ÓÕ.Ä.), ùò ï áñìüäéïò åèíéêüò öïñÝáò,óýìöùíá ìå ôï Í. 3066/2002
ÄÉÁÐÉÓÔÅYÅÉ
ôï
ÅñãáóôÞñéïôçò
ÂÉÏÇÅLLÅÍÉÊÁ Á.Å.
óôç Èåóóáëïíßêç
ÁèÞíá, 8 Öåâñïõáñßïõ 2008
Í. ÐáðáúùÜííïõÐñüåäñïò ôïõ Å.ÓÕ.Ä.
Åèíéêü Óýóôçìá Äéáðßóôåõóçò Á.Å.
ÐÉÓÔÏÐÏÉÇÔÉÊO ÄÉÁÐIÓÔÅÕÓÇÓ
Present and future applications of umbilical cord blood stem cells
Biohellenika SA
is the only Accredited
by ÅÓÕÄ Stem Cell
Cryopreservation
Company
the biggest greek stem cell cryopreservation institution
65, Georgikis Scholis Avenue57001 ThessalonikiZEDA building, 1st floor, entrance 3Tel.: +30 2310 474282, 2310 474284 Fax: +30 2310 474285E-mail: [email protected], www.biohellenika.gr
Biohe enikaBIOTECHNOLOGY COMPANY
Quarterly publication of Biohellenika
immediate availability when needed, provided that they
have been previously collected and cryopreserved when
the donor was healthy, with the prospect of future use.
Umbilical cord blood stem cells have increasingly been
used for autologous and allogeneic transplantations
and are the treatment of choice in cases of patients with
rare histocompatibility types, ethnic minorities, and
where the patient urgently requires a transplant and
cannot wait for the weeks or months required to search
for a compatible donor.
Tse WW et al. Bone Marrow Transplant. 41(5): 465-472,
2008
Due to the easy attainment and the possibility of To d a t e , 2 5 , 0 0 0 h a e m a t o p o i e t i c s t e m c e l l
umbilical cord blood stem cell cryopreservation it is transplantations derived from the placenta, bone
anticipated that in the near future every child will marrow and peripheral blood have been carried out
across Europe. 70% of those were autologous; using the preserve its own stem cells for immediate use, if needed.
patients’ own stem cells. In each case the stem cells were It is anticipated that the use of umbilical cord blood stem
healthy and free of disease. 30% of transplantations were cells will increase dramatically over the next 4 years for allogeneic with stem cells sourced from a compatible the treatment of Acute Myeloblastic Leukemia, Acute donor, who was a relative in 70% of the cases, whereas in Lymphoblastic Leukemia, lymphomas in children and 30% of the cases the donor was unrelated. In a large adults, and autoimmune and cardiovascular diseases.number of cases cryopreserved stem cells were used.
Stem cell cryopreservation has the advantage of Watt SM et al. Methods Mol Biol, 368:237-259, 2007
03NEWSNEWS02
NEWS
Nr 03
nWhen Ltd companies were claiming to be “the only
ones operating under the guidelines of ISO 15189”,
Biohellenika’s scientific team was striving to improve
the quality of their services provided. On 21/02/2008
Biohellenika attained the 410 08/02/2008 accreditation
by the National Accreditation System S.Á (ÅÓÕÄ) granted
for procedures followed and quality testing of umbilical
cord blood during the collection of stem cells. With this
certification, Biohellenika is accredited according to ISO
15189:2007, special for medical laboratories, for
nucleated cell measurement, haematopoietic stem cell
viability and microbial testing, including aerobic,
anaerobic bacteria and fungi. This certificate is valid until
2012 as long as the facility’s operations comply with the
above guidelines during regular ÅÓÕÄ inspections.
The National Accreditation System (ÅÓÕÄ ) is a full
member of the International Laboratory Accreditation
Cooperation (ILAC) since 2004, of the European
Cooperation for Accreditation – EA since 2005, and of the
International Accreditation Forum (IAF-MRA) since 2006.
The international identity of ÅÓÕÄ gives the
perspective of the parity and mutual recognition of
accreditation between countries. Biohellenika today is
the first company in Greece whose laboratories are
accredited by a national independent organization for
measurements and quality control procedures followed
during stem cell collection from umbilical cord blood.
Áñ. 410
Ôo Åèíéêü Óýóôçìá Äéáðßóôåõóçò Á.Å. (Å.ÓÕ.Ä.), ùò ï áñìüäéïò åèíéêüò öïñÝáò,óýìöùíá ìå ôï Í. 3066/2002
ÄÉÁÐÉÓÔÅYÅÉ
ôï
ÅñãáóôÞñéïôçò
ÂÉÏÇÅLLÅÍÉÊÁ Á.Å.
óôç Èåóóáëïíßêç
ÁèÞíá, 8 Öåâñïõáñßïõ 2008
Í. ÐáðáúùÜííïõÐñüåäñïò ôïõ Å.ÓÕ.Ä.
Åèíéêü Óýóôçìá Äéáðßóôåõóçò Á.Å.
ÐÉÓÔÏÐÏÉÇÔÉÊO ÄÉÁÐIÓÔÅÕÓÇÓ
Present and future applications of umbilical cord blood stem cells
Biohellenika SA
is the only Accredited
by ÅÓÕÄ Stem Cell
Cryopreservation
Company
the biggest greek stem cell cryopreservation institution
65, Georgikis Scholis Avenue57001 ThessalonikiZEDA building, 1st floor, entrance 3Tel.: +30 2310 474282, 2310 474284 Fax: +30 2310 474285E-mail: [email protected], www.biohellenika.gr
Biohe enikaBIOTECHNOLOGY COMPANY
Quarterly publication of Biohellenika
0504 NEWSNEWS
nRecently, in the international medical journal JAMA, a
review article of studies published from 1997 till today on
the use of haematopoietic stem cells in autoimmune and
cardiovascular diseases was published. For autoimmune
diseases, 26 multicenter clinical trials representing 854
patients reported clinical improvement, mortality of less
than 1% and prolongation of disease-free survival.
For reports involving cardiovascular diseases, involving
1002 patients with acute myocardial infarction and 493
patients with chronic coronary artery disease, the evidence
suggests that stem cell treatment contributes to
improvement of cardiac function.
Scientists estimate that these results can become even
more promising by determining the most appropriate cell
type, dosage and timing of delivery.
Burt RK et al JAMA, 299(8): 925-936, 2008
nThe use of umbilical cord blood stem cells for
the treatment of metabolic inherited diseases such
as muco-polysaccharidosis is the absolute
indication and offers signif icant cl inical
improvement of the patients.
A l l o g e n e i c h a e m ato p o i e t i c s te m ce l l
transplantation can prolong life and improve its
quality in patients with inherited metabolic
diseases. For better therapeutic results, the earliest
possible initiation of treatment prior to the
occurrence of permanent damage is a necessary
prerequisite.
Stem cells replace those cells that carry the
pathologic, mutated genes, relating to the disease,
and offer a permanent source of normal enzymes
necessary for the metabolism and normal cell
function.
Stem cells may provide an alternative
mechanism of action through cell regeneration or
repair of function of pathological cells.
Prasad VK et al. Bone Marrow Transplant, 41 (2):
99-108, 2008
n
Immunomodulatory effect of mesenchymal stem cells in liver transplantation
n
Umbilical cord contains both mature and immature
progenitor cells, heamatopoietic and mesenchymal
stem cells respectively. Haematopoietic stem cells can
provide effective treatment for haematopoietic
malignancies and diseases of the immune system.
Mesenchymal stem cells comprise of a population of
multipotent precursors capable of differentiating into
various cell lineages such as neurons, chondrocytes,
osetocytes, myocytes, adipocytes and cells of liver, lung,
and pancreatic tissue. These cells are ideal candidates for
tissue engineering and regenerative medicine as they
can contribute to organ function such as the heart after
acute myocardial infarction and the spinal cord after Acute rejection after liver transplantation is usually injury or inflammation. Haematopoietic stem cells can treated with large doses of immunosuppressants with be isolated from umbilical cord blood and placenta in severe and toxic side effects. contrast to mesenchymal stem cells that can mainly be Recent studies by Chinese scientists have shown that found in the stroma of the umbilical cord, also called mesenchymal stem cell transplantation in an orthotopic Wharton’s Jelly, located around the umbilical cord vein liver transplantation animal model significantly and at a lesser extent in umbilical cord blood. alleviated liver acute rejection and at the same time, Mesenchymal stem cells cannot be traced in adults’ inhibited recipient – derived T- lymphocyte proliferation. peripheral blood. Based on the above facts, for a Cytotoxic T-lymphocytes are responsible for acute complete therapeutic treatment stem cell collection rejection of the transplant.from both sources is required. Double collection offers
therapeutic alternatives for haematopoietic and
immune system diseases and for Regenerative Medicine Wan CD et al. Hepatobiliary Pancreat Dis Int 7(1),
applications in tissue (and organ) repair. 29-33, 2008.Biohellenika is the first and only Greek company until
today that has provided double cell collections for free to Secco M et al. Stem Cells 26 (1): 146-150, 2008.families with high risk family history for future
therapeutic treatment with mesenchymal stem cells.
Umbilical cord contains both mature and immature progenitor cells, heamatopoietic and mesenchymal stem cells respectively. Haematopoietic stem cells can provide effective treatment for haematopoietic malignancies and diseases of the immune system.
Clinical applications of umbilical cord blood stem cells for nonmalignant diseases
MESENCHYMAL STEM CELLS:
THE FUTURE OF MODERN MEDICINE
0504 NEWSNEWS
nRecently, in the international medical journal JAMA, a
review article of studies published from 1997 till today on
the use of haematopoietic stem cells in autoimmune and
cardiovascular diseases was published. For autoimmune
diseases, 26 multicenter clinical trials representing 854
patients reported clinical improvement, mortality of less
than 1% and prolongation of disease-free survival.
For reports involving cardiovascular diseases, involving
1002 patients with acute myocardial infarction and 493
patients with chronic coronary artery disease, the evidence
suggests that stem cell treatment contributes to
improvement of cardiac function.
Scientists estimate that these results can become even
more promising by determining the most appropriate cell
type, dosage and timing of delivery.
Burt RK et al JAMA, 299(8): 925-936, 2008
nThe use of umbilical cord blood stem cells for
the treatment of metabolic inherited diseases such
as muco-polysaccharidosis is the absolute
indication and offers signif icant cl inical
improvement of the patients.
A l l o g e n e i c h a e m ato p o i e t i c s te m ce l l
transplantation can prolong life and improve its
quality in patients with inherited metabolic
diseases. For better therapeutic results, the earliest
possible initiation of treatment prior to the
occurrence of permanent damage is a necessary
prerequisite.
Stem cells replace those cells that carry the
pathologic, mutated genes, relating to the disease,
and offer a permanent source of normal enzymes
necessary for the metabolism and normal cell
function.
Stem cells may provide an alternative
mechanism of action through cell regeneration or
repair of function of pathological cells.
Prasad VK et al. Bone Marrow Transplant, 41 (2):
99-108, 2008
n
Immunomodulatory effect of mesenchymal stem cells in liver transplantation
n
Umbilical cord contains both mature and immature
progenitor cells, heamatopoietic and mesenchymal
stem cells respectively. Haematopoietic stem cells can
provide effective treatment for haematopoietic
malignancies and diseases of the immune system.
Mesenchymal stem cells comprise of a population of
multipotent precursors capable of differentiating into
various cell lineages such as neurons, chondrocytes,
osetocytes, myocytes, adipocytes and cells of liver, lung,
and pancreatic tissue. These cells are ideal candidates for
tissue engineering and regenerative medicine as they
can contribute to organ function such as the heart after
acute myocardial infarction and the spinal cord after Acute rejection after liver transplantation is usually injury or inflammation. Haematopoietic stem cells can treated with large doses of immunosuppressants with be isolated from umbilical cord blood and placenta in severe and toxic side effects. contrast to mesenchymal stem cells that can mainly be Recent studies by Chinese scientists have shown that found in the stroma of the umbilical cord, also called mesenchymal stem cell transplantation in an orthotopic Wharton’s Jelly, located around the umbilical cord vein liver transplantation animal model significantly and at a lesser extent in umbilical cord blood. alleviated liver acute rejection and at the same time, Mesenchymal stem cells cannot be traced in adults’ inhibited recipient – derived T- lymphocyte proliferation. peripheral blood. Based on the above facts, for a Cytotoxic T-lymphocytes are responsible for acute complete therapeutic treatment stem cell collection rejection of the transplant.from both sources is required. Double collection offers
therapeutic alternatives for haematopoietic and
immune system diseases and for Regenerative Medicine Wan CD et al. Hepatobiliary Pancreat Dis Int 7(1),
applications in tissue (and organ) repair. 29-33, 2008.Biohellenika is the first and only Greek company until
today that has provided double cell collections for free to Secco M et al. Stem Cells 26 (1): 146-150, 2008.families with high risk family history for future
therapeutic treatment with mesenchymal stem cells.
Umbilical cord contains both mature and immature progenitor cells, heamatopoietic and mesenchymal stem cells respectively. Haematopoietic stem cells can provide effective treatment for haematopoietic malignancies and diseases of the immune system.
Clinical applications of umbilical cord blood stem cells for nonmalignant diseases
MESENCHYMAL STEM CELLS:
THE FUTURE OF MODERN MEDICINE
0706 NEWSNEWS
Mesenchymal stem cells for
transplantation therapy of
traumatic central nervous
system injury and
neurodegenerative
diseases
n
n
Mesenchymal-like cells from cord blood exhibit a
potential for differentiation into neuron-like cells in
culture. Transplantation of umbilical cord blood stem
cells in animal models with ischemic and traumatic
injuries reduced lesion sizes and enhanced behavioral
recovery. Neurons derived from Wharton’s Jelly
mesenchymal cells could alleviate movement disorders
in hemiparkinsonian animal models.
Low CB et al J Neurosci Res, Feb 2008.
Neurogenesis is a natural biological process which
continues to occur throughout life but dramatically
decreases with increasing age. Intravenous injection of
umbilical cord blood in aged animals rejuvenates the
proliferative activity of neural stem cells, induces
neurogenesis and improves the microenvironment of
neural cells due to the decrease of inflammation.
Intravenous injection of umbilical cord blood can be an
effective approach for the treatment of injuries,
neurodegenerative diseases and aging.
Bachstetter AD et al BMC Neurosci, 9(1): 22, 2008.
Mesenchymal
stem cells as a vehicle
for gene therapy of
malignant tumors
nMalignant gliomas represent aggressive, highly
infiltrative types of brain cancer. Current therapeutic
treatment depends on the excision of the tumor and
concurrent chemoradiotherapy, however with poor
outcome. Gene therapy represents a promising
alternative treatment and depends on the property of
mesenchymal stem cells to infiltrate in the malignant
gliomas and deliver oncolytic factors.
A study conducted in the Brain Tumor Center, in
Chicago USA showed that, human mesenchymal stem
cells, after intravenous injection in animal models with
gliomas, can migrate to the site of the tumor and deliver
oncolytic adenoviruses on site and destroy the
malignant tumor. The capability of mesenchymal stem
cells to deliver Nd release oncolytic adenoviruses in
intracranial malignant gliomas is higher than any other
vector used until today.
These results are especially encouraging and future
applications in patients could improve the outcome of
oncolytic virotherapy for gliomas especially in case of
tumors that cannot be surgically excised.
Sonabend AM et al. Stem Cells,, 26(3): 831-841, 2008.
mmunotherapy of
human neuroblastoma
using umbilical cord
blood stem cells
nFor the treatment of nervous system malignancies,
umbilical cord blood was recently used which contains
precursors of antitumor cytotoxic effector cells. In a
comparative study conducted by scientists of the
University of Nebraska, USA it was shown that
transplantation of umbilical cord blood stem cells in
animal models with neuroblastoma resulted in
inhibition of tumor growth and increased overall
survival.
In addition, further investigations showed that umbilical
cord blood stem cells differentiate into cytotoxic T –
lymphocytes which turn against tumor cells and
effectively kill them.
These results demonstrate the potential of UCB derived
effector cells against human neuroblastoma and
warrant further preclinical studies.
Joshi AD et al. l. Neuroimmune Pharmacology 2(2):
202-212, 2007.
Differentiation into
hepatic cells
nThe stromal mucous tissue that protects and
insulates umbilical cord vessels is called Wharton’s Jelly
and is composed mainly of mesenchymal stem cells.
Wharton’s Jelly mesenchymal stem cells were
transplanted into livers of hepatectomized-SCID mice
and exhibited hepatic cell characteristics two weeks
later.
In vitro expanded mesenchymal stem cells
constitutively expressed markers of hepatic lineage.
Wharton’s jelly is a rich and valuable source of
primitive stem cells during birth containing large
numbers of cells similar to those of the umbilical cord
blood.
The properties of Wharton’s jelly mesenchymal stem
cells are similar to those of umbilical cord blood stem
cells.
Campard D, et al Gastrenterology, 134(3): 878-881,
2008.
New applications of umbilical cord blood mesenchymal stem cells.
0706 NEWSNEWS
Mesenchymal stem cells for
transplantation therapy of
traumatic central nervous
system injury and
neurodegenerative
diseases
n
n
Mesenchymal-like cells from cord blood exhibit a
potential for differentiation into neuron-like cells in
culture. Transplantation of umbilical cord blood stem
cells in animal models with ischemic and traumatic
injuries reduced lesion sizes and enhanced behavioral
recovery. Neurons derived from Wharton’s Jelly
mesenchymal cells could alleviate movement disorders
in hemiparkinsonian animal models.
Low CB et al J Neurosci Res, Feb 2008.
Neurogenesis is a natural biological process which
continues to occur throughout life but dramatically
decreases with increasing age. Intravenous injection of
umbilical cord blood in aged animals rejuvenates the
proliferative activity of neural stem cells, induces
neurogenesis and improves the microenvironment of
neural cells due to the decrease of inflammation.
Intravenous injection of umbilical cord blood can be an
effective approach for the treatment of injuries,
neurodegenerative diseases and aging.
Bachstetter AD et al BMC Neurosci, 9(1): 22, 2008.
Mesenchymal
stem cells as a vehicle
for gene therapy of
malignant tumors
nMalignant gliomas represent aggressive, highly
infiltrative types of brain cancer. Current therapeutic
treatment depends on the excision of the tumor and
concurrent chemoradiotherapy, however with poor
outcome. Gene therapy represents a promising
alternative treatment and depends on the property of
mesenchymal stem cells to infiltrate in the malignant
gliomas and deliver oncolytic factors.
A study conducted in the Brain Tumor Center, in
Chicago USA showed that, human mesenchymal stem
cells, after intravenous injection in animal models with
gliomas, can migrate to the site of the tumor and deliver
oncolytic adenoviruses on site and destroy the
malignant tumor. The capability of mesenchymal stem
cells to deliver Nd release oncolytic adenoviruses in
intracranial malignant gliomas is higher than any other
vector used until today.
These results are especially encouraging and future
applications in patients could improve the outcome of
oncolytic virotherapy for gliomas especially in case of
tumors that cannot be surgically excised.
Sonabend AM et al. Stem Cells,, 26(3): 831-841, 2008.
mmunotherapy of
human neuroblastoma
using umbilical cord
blood stem cells
nFor the treatment of nervous system malignancies,
umbilical cord blood was recently used which contains
precursors of antitumor cytotoxic effector cells. In a
comparative study conducted by scientists of the
University of Nebraska, USA it was shown that
transplantation of umbilical cord blood stem cells in
animal models with neuroblastoma resulted in
inhibition of tumor growth and increased overall
survival.
In addition, further investigations showed that umbilical
cord blood stem cells differentiate into cytotoxic T –
lymphocytes which turn against tumor cells and
effectively kill them.
These results demonstrate the potential of UCB derived
effector cells against human neuroblastoma and
warrant further preclinical studies.
Joshi AD et al. l. Neuroimmune Pharmacology 2(2):
202-212, 2007.
Differentiation into
hepatic cells
nThe stromal mucous tissue that protects and
insulates umbilical cord vessels is called Wharton’s Jelly
and is composed mainly of mesenchymal stem cells.
Wharton’s Jelly mesenchymal stem cells were
transplanted into livers of hepatectomized-SCID mice
and exhibited hepatic cell characteristics two weeks
later.
In vitro expanded mesenchymal stem cells
constitutively expressed markers of hepatic lineage.
Wharton’s jelly is a rich and valuable source of
primitive stem cells during birth containing large
numbers of cells similar to those of the umbilical cord
blood.
The properties of Wharton’s jelly mesenchymal stem
cells are similar to those of umbilical cord blood stem
cells.
Campard D, et al Gastrenterology, 134(3): 878-881,
2008.
New applications of umbilical cord blood mesenchymal stem cells.
A research group from the University of Taiwan
isolated mesenchymal stem cells from the Wharton’s
Jelly, which is located around the umbilical cord veins,
and differentiated them into insulin producing â-
pancreatic calls in culture.
Twelve weeks after transplantation of these cells into
animal models with diabetes type I, production of insulin
and C-peptide was observed, which is a by-product of
insulin production.
These findings are encouraging, as mesenchymal
stem cells from Wharton’s jelly exhibit certain
advantages such as:
-Immediate availability upon demand
-Large potential donor pool
-Ease of obtaining without complications
-Rarity of graft versus host disease
-Differentiation ability into insulin producing
pancreatic â-cells.
Urban VS et al. Stem cells , 26(1): 244-253, 2007.
Chao KC et al. PLoS ONE 16:3 (1), 2008.
Proceedings of 67th Scientific Sessions of American
Diabetes Association.
0908 NEWSNEWS
nHuman dental pulp contains precursor cells termed
Mesenchymal Dental Pulp Stem Cells (DPSCs) that
show high self-renewal ability and plasticity, like
mesenchymal stem cells, as they can be differentiated
into multiple cell types.
These special features were further investigated by
scientists in Spain in order to examine whether these
cells could have therapeutic potential in the repair of
myocardial infarction.
DPSCs were injected intramyocardically in animal
models seven days after induction of myocardial
infarction and their impact was observed for four weeks
afterwards. DPSCs were obtained from human dental
pulp of third molars.
DPSCs survived and engrafted in the ischemic area.
The degree of improvement in cardiac function was
similar to that observed after bone marrow stem cell
transplantation. Indeed, improvement in cardiac
function was correlated with reduction in infarct size,
higher capillary network density and increased wall
thickness in DPSC transplanted animals.
In addition, ultrasound analysis of left ventricular wall
peri-infarct zones showed an increase in cardiomyocyte
bundles and a higher proportion of myofibroblasts in
the area, phenomena associated with faster wound
healing and reduction of the infarct size.
The present study showed that DPSCs are able to
repair infarcted myocardium after a cardiac episode,
which is obviously associated with their ability to secrete
anti-apoptotic and pro-angiogenic factors.
These results extend the knowledge of DPSCs’
therapeutical properties and provide a promising source
for the treatment of ischemic diseases.
Gandia C. et al. Stem cells 26(3):638-645, 2008.
The results of the study six months afterwards showed
that:
1) Children that received the cord blood had A1c’s 7%
compared to 8.04% in the control group and required
less insulin.
2) The cord blood group showed little change in the
levels of C-peptide, which indicates an ability to
produce insulin.
3) Finally, there was an increase in the number of T-
regulatory lymphocytes that restrain the immune
system from attacking the pancreas.
These findings render stem cells a valuable tool in the
treatment of diabetes type I, as combination treatment
with conventional cell therapies might arrest or even
prevent the development of diabetes type I.
Similar results were obtained by a research group at
the National Medical Center of Hungary, where studies
in animal models showed that, concomitant
administration of mesenchymal stem cells and bone
marrow cells induces regeneration of recipient derived
pancreatic insulin-secreting cells and at the same time
suppresses activation of the immune system.
Application of this therapy in humans patients may be
feasible for a large number of autoimmune diseases.
A research group from at the University of Florida, USA recently announced (December, 2007) the conduction of a clinical trial where 7 children, aged 2-7 years old, newly diagnosed with Diabetes type I were recruited. They were infused with autologous umbilical cord blood stem cells and the results were compared to those from 13 children treated with insulin (control group).
A
B
C
STEM CELLS AGAINST DIABETES TYPE IHuman Dental Pulp Stem Cells in the treatment
of Acute Myocardial Infarction
Pictures A, B & CHuman dental pulp stem cells.
Biohellenika’s photos
A research group from the University of Taiwan
isolated mesenchymal stem cells from the Wharton’s
Jelly, which is located around the umbilical cord veins,
and differentiated them into insulin producing â-
pancreatic calls in culture.
Twelve weeks after transplantation of these cells into
animal models with diabetes type I, production of insulin
and C-peptide was observed, which is a by-product of
insulin production.
These findings are encouraging, as mesenchymal
stem cells from Wharton’s jelly exhibit certain
advantages such as:
-Immediate availability upon demand
-Large potential donor pool
-Ease of obtaining without complications
-Rarity of graft versus host disease
-Differentiation ability into insulin producing
pancreatic â-cells.
Urban VS et al. Stem cells , 26(1): 244-253, 2007.
Chao KC et al. PLoS ONE 16:3 (1), 2008.
Proceedings of 67th Scientific Sessions of American
Diabetes Association.
0908 NEWSNEWS
nHuman dental pulp contains precursor cells termed
Mesenchymal Dental Pulp Stem Cells (DPSCs) that
show high self-renewal ability and plasticity, like
mesenchymal stem cells, as they can be differentiated
into multiple cell types.
These special features were further investigated by
scientists in Spain in order to examine whether these
cells could have therapeutic potential in the repair of
myocardial infarction.
DPSCs were injected intramyocardically in animal
models seven days after induction of myocardial
infarction and their impact was observed for four weeks
afterwards. DPSCs were obtained from human dental
pulp of third molars.
DPSCs survived and engrafted in the ischemic area.
The degree of improvement in cardiac function was
similar to that observed after bone marrow stem cell
transplantation. Indeed, improvement in cardiac
function was correlated with reduction in infarct size,
higher capillary network density and increased wall
thickness in DPSC transplanted animals.
In addition, ultrasound analysis of left ventricular wall
peri-infarct zones showed an increase in cardiomyocyte
bundles and a higher proportion of myofibroblasts in
the area, phenomena associated with faster wound
healing and reduction of the infarct size.
The present study showed that DPSCs are able to
repair infarcted myocardium after a cardiac episode,
which is obviously associated with their ability to secrete
anti-apoptotic and pro-angiogenic factors.
These results extend the knowledge of DPSCs’
therapeutical properties and provide a promising source
for the treatment of ischemic diseases.
Gandia C. et al. Stem cells 26(3):638-645, 2008.
The results of the study six months afterwards showed
that:
1) Children that received the cord blood had A1c’s 7%
compared to 8.04% in the control group and required
less insulin.
2) The cord blood group showed little change in the
levels of C-peptide, which indicates an ability to
produce insulin.
3) Finally, there was an increase in the number of T-
regulatory lymphocytes that restrain the immune
system from attacking the pancreas.
These findings render stem cells a valuable tool in the
treatment of diabetes type I, as combination treatment
with conventional cell therapies might arrest or even
prevent the development of diabetes type I.
Similar results were obtained by a research group at
the National Medical Center of Hungary, where studies
in animal models showed that, concomitant
administration of mesenchymal stem cells and bone
marrow cells induces regeneration of recipient derived
pancreatic insulin-secreting cells and at the same time
suppresses activation of the immune system.
Application of this therapy in humans patients may be
feasible for a large number of autoimmune diseases.
A research group from at the University of Florida, USA recently announced (December, 2007) the conduction of a clinical trial where 7 children, aged 2-7 years old, newly diagnosed with Diabetes type I were recruited. They were infused with autologous umbilical cord blood stem cells and the results were compared to those from 13 children treated with insulin (control group).
A
B
C
STEM CELLS AGAINST DIABETES TYPE IHuman Dental Pulp Stem Cells in the treatment
of Acute Myocardial Infarction
Pictures A, B & CHuman dental pulp stem cells.
Biohellenika’s photos
n«Noone could tell he had such an operation by The doctors initially isolated mesenchymal stem cells
looking at him» reported Riita Suuronen, a member of from the patient’s fat and cultured them for 2 weeks in a
the medical team at the University of Tampere, to culture medium that contained his own blood serum.
Reuters. When the cells had multiplied sufficiently, they were
The pioneering method was based on the recent transferred onto a «scaffold» shaped like a jaw, that was
discovery that stem cells exist in the adipose tissue of made from biomaterials such as calcium carbonate. The
adults. These cells can be cultured in a lab and generate whole scaffold was then implanted inside the patient’s
muscles, bones or blood vessels. Such transplants, from belly, where it was left to grow for 9 weeks.
the patients own cells, overcome the problem of donor The live transplant was then screwed onto the cranial
histocompatibility. joint of the 65 year old, while vasculosurgeons
The 65 year old Finnish patient had lost his upper jaw connected it with the blood circulation system.
due to a benign tumor and could only eat and talk with The doctors have now submitted their research for
the help of a removable artificial jaw. medical approval.
1110 NEWSNEWS
The scientific team
of BIOHELLENIKA
now offers the unique
service of stem cell
cryopreservation from
deciduous teeth!
Doctors in Finland replaced
the upper jaw of a 65 year old
patient, with a transplant
derived from his own stem
cells. The transplant was left to
from in his belly for 9 weeks.
Lose a tooth? Gain life!!!Deciduous teeth that are intended for this purpose should
be collected by a dentist trained on this service.
Parents are informedoin site by a scientific member of
BIOHELLENIKA. Afterwards, they receive a file folder, where
they complete all the necessary documents and the
application form, accompanied by DENTOLIFE’s special ®collection kit and the Dentosafe preservation liquid, with
all the necessary instructions for use.
Parents inform their dentist and an appointment is
scheduled for the tooth excision.
12 hours prior to the excision, parents store the collection
kit with the preservation liquid refrigerated at 4°C.
On the day of the excision parents take the file folder with
them as some documents are to be filled out by the dentist.
The parents send the collection kit with all the necessary
documents signed to our company (within 24 hours after
excision).
Your child’s cryopreserved stem cells can be at your
immediate disposal upon request.
Every deciduous tooth contains stem cells that can be
cryopreserved and become a valuable source for future
applications of Regenerative Medicine.
They could actually save your child’s or another child.’s
life!
For further information please address your dentist or
contact DENTOLIFE, Customer Services Line
(+30) 801 1199299 or (+30) 6936 660135.
st1 step
nd2 step
rd3 step
PATIENT FROM FINLAND GETS NEW
JAW MADE OF HIS OWN CELLS
Culture of human chondrocytes. Photos of Biohellenika's company
n«Noone could tell he had such an operation by The doctors initially isolated mesenchymal stem cells
looking at him» reported Riita Suuronen, a member of from the patient’s fat and cultured them for 2 weeks in a
the medical team at the University of Tampere, to culture medium that contained his own blood serum.
Reuters. When the cells had multiplied sufficiently, they were
The pioneering method was based on the recent transferred onto a «scaffold» shaped like a jaw, that was
discovery that stem cells exist in the adipose tissue of made from biomaterials such as calcium carbonate. The
adults. These cells can be cultured in a lab and generate whole scaffold was then implanted inside the patient’s
muscles, bones or blood vessels. Such transplants, from belly, where it was left to grow for 9 weeks.
the patients own cells, overcome the problem of donor The live transplant was then screwed onto the cranial
histocompatibility. joint of the 65 year old, while vasculosurgeons
The 65 year old Finnish patient had lost his upper jaw connected it with the blood circulation system.
due to a benign tumor and could only eat and talk with The doctors have now submitted their research for
the help of a removable artificial jaw. medical approval.
1110 NEWSNEWS
The scientific team
of BIOHELLENIKA
now offers the unique
service of stem cell
cryopreservation from
deciduous teeth!
Doctors in Finland replaced
the upper jaw of a 65 year old
patient, with a transplant
derived from his own stem
cells. The transplant was left to
from in his belly for 9 weeks.
Lose a tooth? Gain life!!!Deciduous teeth that are intended for this purpose should
be collected by a dentist trained on this service.
Parents are informedoin site by a scientific member of
BIOHELLENIKA. Afterwards, they receive a file folder, where
they complete all the necessary documents and the
application form, accompanied by DENTOLIFE’s special ®collection kit and the Dentosafe preservation liquid, with
all the necessary instructions for use.
Parents inform their dentist and an appointment is
scheduled for the tooth excision.
12 hours prior to the excision, parents store the collection
kit with the preservation liquid refrigerated at 4°C.
On the day of the excision parents take the file folder with
them as some documents are to be filled out by the dentist.
The parents send the collection kit with all the necessary
documents signed to our company (within 24 hours after
excision).
Your child’s cryopreserved stem cells can be at your
immediate disposal upon request.
Every deciduous tooth contains stem cells that can be
cryopreserved and become a valuable source for future
applications of Regenerative Medicine.
They could actually save your child’s or another child.’s
life!
For further information please address your dentist or
contact DENTOLIFE, Customer Services Line
(+30) 801 1199299 or (+30) 6936 660135.
st1 step
nd2 step
rd3 step
PATIENT FROM FINLAND GETS NEW
JAW MADE OF HIS OWN CELLS
Culture of human chondrocytes. Photos of Biohellenika's company
1312 NEWSNEWS
nTh e s u cce s s f u l co l l a b o rat i o n b e t we e n Biohellenika then ensures that the stem cell
Biohellenika and the Private Maternity Clinic collection procedure is completed without an added
“Genesis” continues. The “Preservation and Safety” burden to the parents. This special care and security is
program offers to parents that choose to give labor at enhanced, without extra cost, by an insurance cover
the “Genesis” Maternity Clinic, a complete service of of up to 50,000€ for the first 5 years of the child’s life
umbilical cord blood stem cell cryopreservation. from the start of the preservation, in case of the need
An increasing number of parents from Thessaloniki for transplantation. The Maternity Clinic “Genesis”
and other neighboring cities are choosing this ensures the preservation for the next 20 years, as
program for preservation of their child’s precious described in a special article in the Private Contract.
stem cells. Upon entry of the parents in the clinic for
the labor, they express their wish to collect their
child’s stem cells. The Clinic in collaboration with
Biohe enikaÅÔÁÉÑÅÉÁ ÂÉÏÔÅ×ÍÏËÏÃÉÁÓ
nOn D ecember 11 , 2007 the opening of Institute's shelter, one of the safest places in Greece. A
BIOHELLENIKA's laboratories in Athens were performed. specific article in the private contract describes that if for
The laboratories in Athens are the product of the any reason the mother company seizes to operate,
collaboration between Biohellenika and the National preservation of all of BIOHELLENIKA's samples will
Research Institute, called the Precursor Cell Bank of continue under the responsibility of the National
National Research Institute, briefly TAK-EIE. Research Institute.
The constant increase in the number of parents from With this collaboration, BIOHELLENIKA aims to promote
South Greece, who showed us their preference and its stem cell applications all over Greece and at the same
trusted us with their children's stem cells, led to the need time, make the procedure more user-friendly for the
to establish laboratories in Athens. With respect to this public.
preference and in an effort to improve the quality of
services provided, considering that the time elapsed
between labor and cryopreservation is now minimized,
BIOHELLENIKA initiated this collaboration with the
National Research Institute. This collaboration with the
National Research Institute has the added benefits of
security and assurance of cryopreservation for the next
20 years.
BIOHELLENIKA preserves cord blood stem cells at two
different locations, after separation into two equal parts,
as described in the private contract. One part is
preserved at Thessaloniki's laboratories and the other
part at TAK-EIE's laboratories, which are housed at the
Preservation and Safety at the Maternity Clinic «Genesis»
OPENING
OF BIOHELLENIKA'S
LABORATORIES IN ATHENS
1312 NEWSNEWS
nTh e s u cce s s f u l co l l a b o rat i o n b e t we e n Biohellenika then ensures that the stem cell
Biohellenika and the Private Maternity Clinic collection procedure is completed without an added
“Genesis” continues. The “Preservation and Safety” burden to the parents. This special care and security is
program offers to parents that choose to give labor at enhanced, without extra cost, by an insurance cover
the “Genesis” Maternity Clinic, a complete service of of up to 50,000€ for the first 5 years of the child’s life
umbilical cord blood stem cell cryopreservation. from the start of the preservation, in case of the need
An increasing number of parents from Thessaloniki for transplantation. The Maternity Clinic “Genesis”
and other neighboring cities are choosing this ensures the preservation for the next 20 years, as
program for preservation of their child’s precious described in a special article in the Private Contract.
stem cells. Upon entry of the parents in the clinic for
the labor, they express their wish to collect their
child’s stem cells. The Clinic in collaboration with
Biohe enikaÅÔÁÉÑÅÉÁ ÂÉÏÔÅ×ÍÏËÏÃÉÁÓ
nOn D ecember 11 , 2007 the opening of Institute's shelter, one of the safest places in Greece. A
BIOHELLENIKA's laboratories in Athens were performed. specific article in the private contract describes that if for
The laboratories in Athens are the product of the any reason the mother company seizes to operate,
collaboration between Biohellenika and the National preservation of all of BIOHELLENIKA's samples will
Research Institute, called the Precursor Cell Bank of continue under the responsibility of the National
National Research Institute, briefly TAK-EIE. Research Institute.
The constant increase in the number of parents from With this collaboration, BIOHELLENIKA aims to promote
South Greece, who showed us their preference and its stem cell applications all over Greece and at the same
trusted us with their children's stem cells, led to the need time, make the procedure more user-friendly for the
to establish laboratories in Athens. With respect to this public.
preference and in an effort to improve the quality of
services provided, considering that the time elapsed
between labor and cryopreservation is now minimized,
BIOHELLENIKA initiated this collaboration with the
National Research Institute. This collaboration with the
National Research Institute has the added benefits of
security and assurance of cryopreservation for the next
20 years.
BIOHELLENIKA preserves cord blood stem cells at two
different locations, after separation into two equal parts,
as described in the private contract. One part is
preserved at Thessaloniki's laboratories and the other
part at TAK-EIE's laboratories, which are housed at the
Preservation and Safety at the Maternity Clinic «Genesis»
OPENING
OF BIOHELLENIKA'S
LABORATORIES IN ATHENS
With dedication and using the highest technology, it
ensures your child's stem cell preservation and at the
same time, provides it with a lifetime health service. One
of these is BIOHELLENIKA's initiation of a collaboration
with an insurance company, providing a free life insurance
for the first 5 years from the day of preservation, and for a
total amount of 50,000€. This insurance program has
retrospective value and includes all children from the
beginning of BIOHELLENIKA's operations. It concerns
umbilical cord blood stem cell transplantation as a
therapeutic treatment of malignant diseases and covers
hospitalization in Greece and abroad. Many parents have
already received the insurance contracts of their children
and it is anticipated that the rest of the contracts will be
sent in the near future.
The program covers the case of autologous
transplantation and provides the following services:
coverage of hospitalization fees, medicines, examinations
and medical actions in Greece or abroad. Secure
transportation of the family and the stem cells inside a
special container, to the site of transplantation abroad.
1514 NEWSNEWS
BIOHELLENIKA, one of the lead
companies in Greece in the field
of biotechnology supports your
family from the moment of the
birth of your child.
Haemostasis is a novel service by BIOHELLENIKA
that operates under the scientific management
and inspection of the Professor of Haematology
Dr. Pantelis Makris. This service is provided during
the medical examination of pregnant women
with a history of repetitive miscarriages and with
a family history of thromboembolic episodes. In
all the above cases a medical examination of the
haemostasis is required.
For the third time in the year 2007 Biohellenika’s research ream was awarded for their work.
stThe 1 award was granted in April 2007 at the 22nd North Greece Conference by the Medical Society of Thessaloniki, regarding the transformation of progenitor cells from the bone marrow to cells of the myocardium, in order to be used in patients with myocardial infarction.
ndThe 2 award was granted in May 2007 by from the Athens Medical Society at their Pan-hellenic Medical Conference, for the research in stem cells derived from the placenta after a special draining technique, which have multipotent capabilities.
rdThe 3 award was granted in December 2007 by the Pan-hellenic Transplantation Society at their 15th Pan-hellenic Conference, for the research on the method of isolating stem cells from the placenta that contains a large number of cells, enough for therapy in adult patients and patients with a large body mass.
On 20/2/2009 Biohellenika received the Accreditation Certificate Nr. Áñ 410 8/2/2008 from ÅÓÕÄ, for its laboratories, which is valid until 2012 under the provision of continuous compliance.
Collaborations:Biohellenika announces the beginning of a collaboration with the Institute of Biotechnology for Western Greece based in Ioannina.
Biohellenika announces the beginning of a collaboration with the University Haematology Clinic of Skopje.
Expansion of Biohellenika in:
Cyprus: Tel (+30) 6944865657
Skopje: Ul Orce Nikolov, br 141-5 1000 Skopje FYROM, Tel: 023217616, 3217652
Biohellenika announces the opening of offices in Patras and Çeraklion for the better service of parents in Pelopponese and Crete, respectively.
The offices in Patras are housed at 3 Ko and Panepistimiou Street and the contact numbers are: (+30) 2610437436, 6978483170.
The offices in Heraklion are housed at 17 Amalthias and Katechaki Street and the contact number is: (+30) 6970803497.
Your Blood
is your shield...
have you checked it?
Group Insurance
for Biohellenika's
children
With dedication and using the highest technology, it
ensures your child's stem cell preservation and at the
same time, provides it with a lifetime health service. One
of these is BIOHELLENIKA's initiation of a collaboration
with an insurance company, providing a free life insurance
for the first 5 years from the day of preservation, and for a
total amount of 50,000€. This insurance program has
retrospective value and includes all children from the
beginning of BIOHELLENIKA's operations. It concerns
umbilical cord blood stem cell transplantation as a
therapeutic treatment of malignant diseases and covers
hospitalization in Greece and abroad. Many parents have
already received the insurance contracts of their children
and it is anticipated that the rest of the contracts will be
sent in the near future.
The program covers the case of autologous
transplantation and provides the following services:
coverage of hospitalization fees, medicines, examinations
and medical actions in Greece or abroad. Secure
transportation of the family and the stem cells inside a
special container, to the site of transplantation abroad.
1514 NEWSNEWS
BIOHELLENIKA, one of the lead
companies in Greece in the field
of biotechnology supports your
family from the moment of the
birth of your child.
Haemostasis is a novel service by BIOHELLENIKA
that operates under the scientific management
and inspection of the Professor of Haematology
Dr. Pantelis Makris. This service is provided during
the medical examination of pregnant women
with a history of repetitive miscarriages and with
a family history of thromboembolic episodes. In
all the above cases a medical examination of the
haemostasis is required.
For the third time in the year 2007 Biohellenika’s research ream was awarded for their work.
stThe 1 award was granted in April 2007 at the 22nd North Greece Conference by the Medical Society of Thessaloniki, regarding the transformation of progenitor cells from the bone marrow to cells of the myocardium, in order to be used in patients with myocardial infarction.
ndThe 2 award was granted in May 2007 by from the Athens Medical Society at their Pan-hellenic Medical Conference, for the research in stem cells derived from the placenta after a special draining technique, which have multipotent capabilities.
rdThe 3 award was granted in December 2007 by the Pan-hellenic Transplantation Society at their 15th Pan-hellenic Conference, for the research on the method of isolating stem cells from the placenta that contains a large number of cells, enough for therapy in adult patients and patients with a large body mass.
On 20/2/2009 Biohellenika received the Accreditation Certificate Nr. Áñ 410 8/2/2008 from ÅÓÕÄ, for its laboratories, which is valid until 2012 under the provision of continuous compliance.
Collaborations:Biohellenika announces the beginning of a collaboration with the Institute of Biotechnology for Western Greece based in Ioannina.
Biohellenika announces the beginning of a collaboration with the University Haematology Clinic of Skopje.
Expansion of Biohellenika in:
Cyprus: Tel (+30) 6944865657
Skopje: Ul Orce Nikolov, br 141-5 1000 Skopje FYROM, Tel: 023217616, 3217652
Biohellenika announces the opening of offices in Patras and Çeraklion for the better service of parents in Pelopponese and Crete, respectively.
The offices in Patras are housed at 3 Ko and Panepistimiou Street and the contact numbers are: (+30) 2610437436, 6978483170.
The offices in Heraklion are housed at 17 Amalthias and Katechaki Street and the contact number is: (+30) 6970803497.
Your Blood
is your shield...
have you checked it?
Group Insurance
for Biohellenika's
children
1
Biohe enikathe biggest greek stem cell cryopreservation
institution
THESSALONIKI
ATHENS
National Institute of Research
TAK.EIE
LARISSA
PATRA
IOANNINA
IRAKLION, CRETE
OPEN LINE801-11-99299
Laboratories - Offices65, Georgikis Scholis Avenue, 57001 ThessalonikiZEDA building, 1st floor, entrance 3Tel.: 2310 474282, 2310 474284 Fax: 2310 474285E-mail: [email protected], www.biohellenika.grOffices:137 Tsimiski Str., 6th floorTel.: 2310 274286 (17:00-21:00 daily)
Offices:2 Mesogion Str, Athens Tower, Building B, 2nd floorTel.: 210 7708882, 210 77008218 Fax: 210 7790788Laboratories:
48 Vasileos Konstantinou Str. 11635 Athens
28A Archelaou Str., 11635 AthensTel. 210 7299140
3 Megalou Alexandrou Str. 6th floor, 41222Tel.: 2410 535603, 6973 984260
Kos 18 & Panepistimiou 3Tel.: 2610 437436, 6978 483170
Technological Park, Pedini Tel.: 26510 44141, 26510 44145
17 Amaltheias & Katechaki Str. Tel.: 6970 803497
Calls only from line phone
17th November Str., PileaMB 16513, PC 54301,ThessalonikiTel.: 2310 984000, Fax: 2310 984469E-mail: [email protected]
Scientific Consultants:
K. Kouzi, MD Associate Professor Histology – Embryology, AUTh, Cell phone: +30 6944 677746
G. Koliakos, MD Associate Professor of Biochemistry, AUTh
clinical trials Accreditation Number 410
BIOTECHNOLOGY COMPANY